{"id":"carisbamate","rwe":[{"pmid":"41371876","year":"2025","title":"Expanding the toolkit: An update on the evolution of new therapies for Lennox-Gastaut Syndrome.","finding":"","journal":"Seminars in pediatric neurology","studyType":"Clinical Study"},{"pmid":"40364147","year":"2025","title":"Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"37655228","year":"2023","title":"Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.","finding":"","journal":"Therapeutic advances in neurological disorders","studyType":"Clinical Study"},{"pmid":"37626674","year":"2023","title":"Modulating Hyperpolarization-Activated Cation Currents through Small Molecule Perturbations: Magnitude and Gating Control.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"},{"pmid":"37293624","year":"2023","title":"Concerted suppressive effects of carisbamate, an anti-epileptic alkyl-carbamate drug, on voltage-gated Na(+) and hyperpolarization-activated cation currents.","finding":"","journal":"Frontiers in cellular neuroscience","studyType":"Clinical Study"}],"tags":[{"label":"carisbamate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N03AX19","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["RWJ-333369","carisbamate"],"offLabel":[],"synonyms":["RWJ-333369","carisbamate"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"carisbamate","explanation":"Imagine your nerves are like electrical wires that carry signals throughout your body. Carisbamate works by changing the way these wires work, which can help reduce the abnormal electrical activity that can cause seizures or other conditions.","oneSentence":"Carisbamate is thought to modulate voltage-gated sodium channels, which are involved in the transmission of nerve impulses.","technicalDetail":"Carisbamate is believed to act as a voltage-gated sodium channel modulator, potentially stabilizing the inactivated state of the channel and reducing the frequency of action potential firing."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4400","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CARISBAMATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARISBAMATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:10:47.619722","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:21.657992+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"phenacemide","drugSlug":"phenacemide","fdaApproval":"1951-06-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lamotrigine","drugSlug":"lamotrigine","fdaApproval":"1994-12-27","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felbamate","drugSlug":"felbamate","fdaApproval":"1993-07-29","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"levetiracetam","drugSlug":"levetiracetam","fdaApproval":"1999-11-30","patentExpiry":"Sep 3, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"zonisamide","drugSlug":"zonisamide","fdaApproval":"2000-03-27","patentExpiry":"Aug 18, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"stiripentol","drugSlug":"stiripentol","fdaApproval":"2018-08-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lacosamide","drugSlug":"lacosamide","fdaApproval":"2008-10-28","patentExpiry":"Jun 5, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"retigabine","drugSlug":"retigabine","fdaApproval":"2011-06-10","relationship":"same-class"},{"drugName":"perampanel","drugSlug":"perampanel","fdaApproval":"2012-10-22","patentExpiry":"Jul 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"brivaracetam","drugSlug":"brivaracetam","fdaApproval":"2016-02-18","patentExpiry":"Feb 21, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cenobamate","drugSlug":"cenobamate","fdaApproval":"2019-11-21","patentExpiry":"Oct 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ganaxolone","drugSlug":"ganaxolone","fdaApproval":"2022-03-18","patentExpiry":"Sep 30, 2042","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"carisbamate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phenacemide","brandName":"phenacemide","genericName":"phenacemide","approvalYear":"1951","relationship":"same-class"},{"drugId":"lamotrigine","brandName":"lamotrigine","genericName":"lamotrigine","approvalYear":"1994","relationship":"same-class"},{"drugId":"felbamate","brandName":"felbamate","genericName":"felbamate","approvalYear":"1993","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"levetiracetam","brandName":"levetiracetam","genericName":"levetiracetam","approvalYear":"1999","relationship":"same-class"},{"drugId":"zonisamide","brandName":"zonisamide","genericName":"zonisamide","approvalYear":"2000","relationship":"same-class"},{"drugId":"stiripentol","brandName":"stiripentol","genericName":"stiripentol","approvalYear":"2018","relationship":"same-class"},{"drugId":"lacosamide","brandName":"lacosamide","genericName":"lacosamide","approvalYear":"2008","relationship":"same-class"},{"drugId":"retigabine","brandName":"retigabine","genericName":"retigabine","approvalYear":"2011","relationship":"same-class"},{"drugId":"perampanel","brandName":"perampanel","genericName":"perampanel","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05219617","phase":"PHASE3","title":"Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults","status":"RECRUITING","sponsor":"SK Life Science, Inc.","startDate":"2022-04-28","conditions":["Seizures","Lennox Gastaut Syndrome"],"enrollment":252,"completionDate":"2028-12"},{"nctId":"NCT04062981","phase":"PHASE1","title":"Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2019-05-03","conditions":["Lennox Gastaut Syndrome"],"enrollment":15,"completionDate":"2022-12-14"},{"nctId":"NCT03731715","phase":"PHASE1","title":"Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2019-02-07","conditions":["Lennox Gastaut Syndrome"],"enrollment":18,"completionDate":"2022-06-29"},{"nctId":"NCT04520360","phase":"PHASE1","title":"Bioavailability and Food Effect Study of 3 Types of Carisbamate","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2020-08-27","conditions":["Healthy Subjects"],"enrollment":33,"completionDate":"2021-10-06"},{"nctId":"NCT02435381","phase":"PHASE1,PHASE2","title":"Carisbamate as a Potential Treatment for Alcohol Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-02","conditions":["Alcohol Dependence","Alcohol Abuse","Substance Abuse"],"enrollment":11,"completionDate":"2013-09-30"},{"nctId":"NCT00492323","phase":"PHASE2","title":"An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2007-03","conditions":["Postherpetic Neuralgia","Neuralgia","Herpes Zoster"],"enrollment":91,"completionDate":"2008-06"},{"nctId":"NCT00501202","phase":"PHASE2","title":"Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2007-03","conditions":["Diabetic Neuropathy, Painful","Diabetic Neuralgia","Diabetic Polyneuropathy","Diabetic Mononeuropathy"],"enrollment":132,"completionDate":"2008-05"},{"nctId":"NCT00744731","phase":"PHASE3","title":"An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2009-01","conditions":["Epilepsy, Partial, Motor","Epilepsy, Complex Partial","Epilepsy, Simple Partial","Focal Motor Epilepsy"],"enrollment":403,"completionDate":"2010-08"},{"nctId":"NCT00991757","phase":"PHASE3","title":"An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2007-02","conditions":["Epilepsy","Complex Partial Seizures","Epilepsy, Complex Partial","Epilepsies, Partial"],"enrollment":991,"completionDate":"2010-10"},{"nctId":"NCT00563459","phase":"PHASE3","title":"Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.","status":"TERMINATED","sponsor":"SK Life Science, Inc.","startDate":"2007-11","conditions":["Epilepsy","Seizures"],"enrollment":89,"completionDate":"2010-04"},{"nctId":"NCT00210522","phase":"PHASE2","title":"An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2005-05","conditions":["Epilepsy","Epilepsies, Partial"],"enrollment":421,"completionDate":"2010-06"},{"nctId":"NCT00210652","phase":"PHASE2","title":"An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2004-07","conditions":["Epilepsy","Epilepsies, Partial"],"enrollment":47,"completionDate":"2010-03"},{"nctId":"NCT00870454","phase":"PHASE2","title":"An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2009-05","conditions":["Diabetic Neuropathies"],"enrollment":386,"completionDate":"2010-12"},{"nctId":"NCT00524056","phase":"PHASE2","title":"A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2007-08","conditions":["Essential Tremor, Movement Disorders"],"enrollment":62,"completionDate":"2008-03"},{"nctId":"NCT00740623","phase":"PHASE3","title":"A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2009-01","conditions":["Epilepsy, Partial, Motor","Epilepsy, Complex Partial","Epilepsy, Simple Partial","Focal Motor Epilepsy"],"enrollment":547,"completionDate":"2010-04"},{"nctId":"NCT00697762","phase":"PHASE3","title":"Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures","status":"TERMINATED","sponsor":"SK Life Science, Inc.","startDate":"2007-10","conditions":["Seizures"],"enrollment":56,"completionDate":"2008-05"},{"nctId":"NCT00697918","phase":"PHASE3","title":"Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2008-03","conditions":["Seizures"],"enrollment":11,"completionDate":"2009-04"},{"nctId":"NCT00228969","phase":"PHASE2","title":"Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2005-02","conditions":["Refractory Epilepsy"],"enrollment":0,"completionDate":"2006-05"},{"nctId":"NCT00109083","phase":"PHASE2","title":"A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2002-03","conditions":["Migraine Headaches"],"enrollment":300,"completionDate":"2006-02"},{"nctId":"NCT00425282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2006-11","conditions":["Epilepsy","Epilepsy, Focal","Seizure Disorder","Complex Partial Seizures","Epilepsy, Complex Partial"],"enrollment":566,"completionDate":"2007-10"},{"nctId":"NCT00433667","phase":"PHASE3","title":"A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2006-11","conditions":["Epilepsy","Epilepsy, Focal","Seizure Disorder","Complex Partial Seizures","Epilepsy, Complex Partial"],"enrollment":563,"completionDate":"2007-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P7725I9V3Z","INN_ID":"8816","UMLSCUI":"C1871983","ChEMBL_ID":"CHEMBL2087003","KEGG_DRUG":"D06573","DRUGBANK_ID":"DB12338","PUBCHEM_CID":"6918474","MESH_SUPPLEMENTAL_RECORD_UI":"C518914"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":75,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N03AX19","allCodes":["N03AX19"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"41371876","title":"Expanding the toolkit: An update on the evolution of new therapies for Lennox-Gastaut Syndrome.","journal":"Seminars in pediatric neurology"},{"date":"2025 Apr 30","pmid":"40364147","title":"Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research.","journal":"Journal of clinical medicine"},{"date":"2023","pmid":"37655228","title":"Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.","journal":"Therapeutic advances in neurological disorders"},{"date":"2023 Aug 2","pmid":"37626674","title":"Modulating Hyperpolarization-Activated Cation Currents through Small Molecule Perturbations: Magnitude and Gating Control.","journal":"Biomedicines"},{"date":"2023","pmid":"37293624","title":"Concerted suppressive effects of carisbamate, an anti-epileptic alkyl-carbamate drug, on voltage-gated Na(+) and hyperpolarization-activated cation currents.","journal":"Frontiers in cellular neuroscience"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CARISBAMATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carisbamate is being investigated as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) in children and adults. It is also being studied as a potential treatment for seizures, epilepsy, and focal seizure disorder.","enrichmentLevel":5,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-12-31T00:00:00.000Z","mah":"Janssen-Cilag International NV","brand_name_local":"Comfyde","application_number":"EMEA/H/C/001221"}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:21.657992+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}